IRBM’s drug discovery research is featured on the cover of this issue’s ACS Publications’ Medicinal Chemistry Letters

The publication describes the discovery of a novel series of Imidazopyrazine derivatives by IRBM’s drug discovery team. This novel series of SHP2 allosteric inhibitors, having an imidazopyrazine 6,5-fused heterocyclic system as central scaffold, showed an excellent potency in enzyme and cellular assays. X-ray studies confirmed novel stabilizing interactions with respect to known SHP2 inhibitors. These compounds paved the way to the discovery of preclinical candidates.